Hub Services / Patient Support Programs

Analysis

340B Contract Pharmacy Restrictions: What Manufacturers and Vendors Need to Know in 2026

2026 field guide to 340B contract pharmacy restrictions: manufacturer policies, Eighth/Third/D.C. Circuit rulings, state laws, the vacated rebate pilot, and vendor selection impact.

Analysis

AI Disruption in Pharma Services: Market Structure Implications

AI will change pharma services economics first by compressing routine administrative labor, not by replacing the full hub, specialty-pharmacy, or patient-services operating model. The strongest current use cases are high-volume PA, BV, document intake, payer-status calls, and workflow triage; the weakest are clinical counseling, rare-disease judgment, CGT coordination, and accountable patient support.

Analysis

AI Hub Operations ROI: What Manufacturers Should Expect

Framework for evaluating AI hub operations ROI in pharma patient support: labor savings, time-to-therapy lift, abandonment reduction, quality risk, and savings pass-through.

Analysis

AI Prior Authorization Platform Comparison: Six Vendors Reshaping PA Automation

Head-to-head analysis of six AI-native prior authorization platforms — Infinitus Systems, Tandem AI, Cohere Health, Coral AI, Neon Health, and SuperDial — spanning voice AI, document AI, and agentic workflow architectures, with implications for CMS-0057-F compliance and pharma manufacturer hub operations.

Comparison

AI Prior Authorization Vendors: Infinitus vs SuperDial vs Neon Health vs Coral AI

Head-to-head comparison of four AI-native prior authorization automation vendors targeting different segments of the pharma patient access workflow. Represents the emerging question of where AI inserts into the PA process: voice-based payer call automation (Infinitus, SuperDial), end-to-end multi-channel workflow orchestration (Neon Health), or pre-submission document AI (Coral AI).

Analysis

Big Three PBM Specialty Pharmacy Operations

The Big Three PBM specialty pharmacies are not simply large dispensing vendors; they are vertically integrated control points that combine formulary leverage, network steering, specialty fulfillment, copay/maximizer economics, and private-label biosimilar strategy.

Analysis

Biosimilar Launch Playbook: Hub, Copay & SP Strategy

Analysis of the hub services, copay assistance, and specialty pharmacy strategy specific to biosimilar launches — a structurally different commercial model from innovator biologics that requires recalibrated vendor selection, program design, and economic assumptions.

Analysis

Cell & Gene Therapy Commercialization: The Services Landscape in 2026

The CGT vendor stack is categorically different from specialty biologics. FACT sites, cryo-chain logistics, one-time pricing, and outcomes-based contracts reshape every service line.

Analysis

Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS

This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.

Analysis

CMS-0057-F Vendor Readiness Matrix: Who's Ready for January 2027

CMS-0057-F turns prior authorization interoperability from a policy aspiration into a dated procurement event. The winners are not simply vendors that can say "FHIR" in a sales deck; they are vendors with production payer deployments, coverage across the relevant Da Vinci implementation guides, integration paths into core admin and provider workflows, and enough decisioning logic to improve actual PA cycle time.

Analysis

Conflict of Interest in Pharma Commercial Services: A Manufacturer's Framework

Conflict of interest is now a core vendor-selection variable in pharma commercialization, not a legal afterthought. PBM-owned specialty pharmacies, distributor-owned hubs, full-stack commercialization platforms, copay maximizer operators, and data-rich service vendors can all create value through integration, but the same integration can redirect prescriptions, obscure economics, constrain data rights, or weaken manufacturer control over the patient journey.

Comparison

ConnectiveRx vs EVERSANA: Hub Services Head-to-Head Comparison

Head-to-head comparison of ConnectiveRx and EVERSANA for hub services and patient support programs. Represents the core architectural question facing pharmaceutical buyers: focused specialist vs. full-stack commercialization partner.

Comparison

Contract Sales Organizations (CSOs) for Pharma: Syneos vs Inizio vs Publicis vs Indegene Comparison

Head-to-head comparison of the major contract sales organizations serving pharma: Syneos Health, Inizio Engage, Publicis Health, Indegene, and EVERSANA.

Comparison

Pharma Copay Program Vendors: ConnectiveRx vs Valeris vs Phil vs Apollo Care

Head-to-head comparison of four copay and financial assistance platforms for pharmaceutical manufacturers. Spans legacy per-redemption processors to digital-first orchestration.

Analysis

CSO Market Post-Restructuring: Syneos, Inizio, and the New Competitive Order

The CSO market is moving away from pure field-force rental toward integrated commercialization, patient solutions, analytics, and flexible deployment. Syneos and Inizio still anchor the scale market, but both are reshaped by PE ownership, leverage, restructuring, and the permanent reduction in traditional in-person field demand.

Comparison

Data & Analytics Platforms: IQVIA vs Komodo Health vs Definitive Healthcare vs ConcertAI

Head-to-head comparison of the four dominant data and analytics platforms for pharma commercial operations. Represents the ecosystem question facing procurement teams: legacy incumbent (IQVIA) versus patient-journey challenger (Komodo Health) versus institutional intelligence specialist (Definitive Healthcare) versus oncology-specific AI platform (ConcertAI).

Analysis

Digital Access Operating Models: Affordability, Hub, and Direct-to-Patient

Buyer guide to pharma digital access models across affordability, hub, and DTP programs, comparing TailorMed, RIS Rx, BlinkRx, Phil, Gifthealth, Fuze Health, Atlantis Health, and IntegriChain.

Analysis

EVERSANA Patient Services: Full-Stack Commercialization Model

This analysis is derived from EVERSANA's Patient Services General Capabilities Deck (2024), a 49-page presentation detailing their integrated patient services and commercialization platform. EVERSANA represents the most complete example of a "full-stack" pharma commercialization partner -- a model that bundles advisory, field deployment, patient services, specialty pharmacy, market access, and data analytics under one roof.

Guide

Field Reimbursement Managers (FRMs): What They Do, Cost, and How to Deploy

Operator guide to FRM programs: functions, loaded-cost modeling, territory sizing, deployment vendors, hub integration, and ROI measurement for specialty launches.

Analysis

GLP-1 Services Crunch: Which Pharma Services Vendors Scale to 10M Patients?

Institutional analysis of which pharma services vendors can scale to GLP-1 volumes. Hubs, AI-PA, retail shift, DTC/telehealth, compounding, and the 2027 IRA reset.

Comparison

Health System SP Accelerators: Shields vs Clearway Health vs CarePathRx vs CPS Solutions

Buyer comparison of the four most relevant health-system specialty pharmacy accelerators in 2026, focused on independence, stack breadth, and structural channel risk.

Analysis

Hub Services Pricing Benchmarking: What Should Manufacturers Pay?

Hub pricing is opaque because vendors price capacity, transactions, patients, technology, and outcomes in different combinations, while manufacturers often benchmark proposals too late in the launch process. The practical thesis is that hub cost should be evaluated against workflow complexity and revenue impact, not against a generic rate card.

Analysis

Hub Services RFP Framework: What Pharma Buyers Evaluate

This analysis is synthesized from hub-services RFP requirements, public operating benchmarks, and vendor capability materials. It provides a comprehensive view of what pharmaceutical companies look for when selecting a hub services vendor -- essential context for understanding competitive dynamics and vendor differentiation in the hub market.

Analysis

Hub Services Buyer's Guide 2026: Complete Vendor Evaluation Framework

Practical RFP and diligence guide for evaluating hub services vendors across technology, operations, access support, affordability, clinical services, reporting, compliance, implementation, and contract protections.

Analysis

Hub Services Market Analysis: U.S. Pharmaceutical Patient Support Programs

U.S. hub services landscape analysis covering market-size caveats, competitive tiers, M&A, technology shifts, and buyer implications for pharma patient-support programs.

Comparison

Best Hub Services Platforms: ConnectiveRx vs AssistRx vs CareMetx vs EVERSANA

Head-to-head hub platform comparison for manufacturers deciding whether ConnectiveRx, AssistRx, CareMetx, or EVERSANA best fits the patient-access operating model.

Analysis

IRA Maximum Fair Price: What Rounds 2-3 Mean for Hub, Copay, and Specialty Pharmacy Vendors

How IRA Medicare negotiation Rounds 2-3 (2027-2028 MFPs) restructure vendor economics across hubs, copay, specialty pharmacy, 340B, and market access consulting.

Comparison

Market Access Consulting Deep Dive: Pricing, GTN, IRA Modeling, and How Top Firms Differ in 2026

Deep dive on market access consulting: firm tiers, typical engagement pricing, IRA MFP modeling, GTN waterfall work, and how Trinity, Avalere, Precision AQ, ZS, Bain, and others differ.

Guide

Medical Affairs & MSL Outsourcing: Build vs Buy for Pharma Launch Teams

Build vs buy framework for pharma medical affairs and MSL deployment. Cost benchmarks, vendor comparison across Inizio, Syneos, Indegene, EVERSANA, Lumanity, and Red Nucleus.

Guide

Oncology Launch: Vendor Stack Playbook for Commercial Teams

The vendor stack for an oncology launch: hub services, specialty pharmacy, field reimbursement, RWE, and medical affairs, mapped by route of administration.

Analysis

Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection

This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.

Analysis

Part D Redesign 2025-2026: The End of Copay Accumulators and the New Patient Economics

How the 2025 Part D redesign, $2,000 OOP cap, Manufacturer Discount Program, and smoothing rewrite manufacturer economics and neutralize accumulator value.

Analysis

Payer Landscape Overview: Plan Design, Self-Insured Dynamics & Formulary Strategies

Analysis of the U.S. commercial and government payer landscape as it relates to pharmaceutical services vendor selection. This page provides the demand-side context that shapes hub services, copay assistance, specialty pharmacy, and prior authorization vendor requirements.

Analysis

PBM-Owned vs Independent Specialty Pharmacy Competitive Analysis

PBM-owned specialty pharmacies dominate by structural control over formulary, network, and captive lives; independent and health-system specialty pharmacies compete on clinical depth, manufacturer alignment, data transparency, and limited-distribution execution. For manufacturers, the optimal network is therefore product-specific rather than ideology-specific.

Analysis

PBM Reform 2026: What CAA, FTC, State Divestitures, and Transparency Rules Mean for Pharma Vendor Strategy

How the FTC Express Scripts settlement, CAA 2026, Arkansas Act 624, and federal delinking proposals are reshaping specialty pharmacy, hub services, and manufacturer GTN strategy.

Analysis

PBM Reform Implications for Pharma Services Vendors

PBM reform is accelerating across federal, state, and regulatory levels. The convergence of the FTC investigation, Consolidated Appropriations Act of 2026 (CAA), state PBM divestiture legislation, and copay accumulator/maximizer restrictions is reshaping the competitive landscape for every pharma services vendor category. This analysis maps the specific implications for hub services, specialty pharmacies, copay assistance vendors, and market access consultants.

Guide

Pharma Services Explained: Hub, Specialty Pharmacy, FRM, and How They Fit Together

Lexicon guide to the pharma commercial services stack. Hub vs specialty pharmacy vs field reimbursement vs copay processor vs market access, with pricing models and named vendors.

Analysis

US Pharma Services Market Sizing and 2025 Update

Directional U.S. pharma services market sizing across specialty pharmacy, prior authorization and reimbursement support, copay programs, market access consulting, data/RWE, and commercial technology, with the 2025 banking-report update folded into one public market map.

Guide

Rare Disease Launch: Vendor Stack Playbook

A prescriptive vendor-stack playbook for rare disease launch teams — sequenced T-18 to T+6 with named vendors, pricing benchmarks, and decision trade-offs for orphan drug commercialization.

Analysis

Specialty Pharmacy Competitive Landscape

U.S. specialty pharmacy landscape analysis covering PBM-owned scale platforms, independent clinical specialists, and health-system specialty pharmacy growth.

Analysis

State Prior Authorization Reform Tracker: Gold Carding, CMS-0057, and Vendor Implications

State prior authorization reform tracker for pharma services vendors, covering gold carding, CMS-0057-F interplay, and vendor implications.

Analysis

Therapeutic Area Specialization Guide: How Hub and SP Workflows Differ by Disease

Therapeutic area specialization is the most common source of false comparability in hub and specialty-pharmacy RFPs. Oncology, rare disease, autoimmune, GLP-1/metabolic, and CGT programs use overlapping vendor categories, but the work is fundamentally different: buy-and-bill versus pharmacy benefit, high-touch case management versus high-volume automation, oral adherence versus chain-of-identity logistics, and biosimilar/formulary defense versus patient finding.

Listicle

Top 12 Real-World Evidence (RWE) Vendors for Pharma in 2026

Ranking of the 12 leading real-world evidence vendors for pharma in 2026, covering claims, EHR, genomic, patient-reported, and integrated RWD providers.

Listicle

Top 10 Specialty Pharmacies for Pharma Manufacturers (2026)

Ranking and analysis of the top 10 specialty pharmacies serving pharma manufacturers, covering PBM-owned, independent, payer-owned, retail-adjacent, and health-system accelerator models.

Analysis

Vertical Integration Economics in Pharma Services

Vertical integration creates real operating value but transfers bargaining power and data control away from manufacturers. PBM/SP/insurer stacks, distributor/hub/pharmacy stacks, and full-stack commercialization platforms all promise fewer handoffs, richer data, and simpler accountability.